Gastric Cancer

From PR Newswire 29/12/2015
Part of article
" .... In 2014, there were a total of 312,520 diagnosed incident cases of gastric cancer in the 8 Major Markets (US, France, Germany, Italy, Spain, UK, Japan & Urban China). GlobalData epidemiologists forecast that the diagnosed incident cases of gastric cancer in the 8MM will increase to 364,518 cases by 2024 at an Annual Growth Rate (AGR) of 1.66%. In the 8MM, urban China had the highest number of diagnosed incident cases (134,968 cases) in 2014, and is expected to grow to 177,015 cases by 2024 at a high AGR of 3.12%.
GlobalData epidemiologists' forecast for gastric cancer is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident gastric cancer cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the gastric cancer patient pool for each country by age, sex, and stage at diagnosis. Additionally, GlobalData's analysis provides diagnosed incident cases of GEJ cancer and segmentation of diagnosed gastric cancer incident cases by cellular type and HER2 status. The forecast is driven by a thorough analysis of historical data. The forecast methodology was also consistent across all the 8MM, thereby allowing for a meaningful comparison of the forecast diagnosed incident and five-year diagnosed prevalent cases of gastric cancer across the 8MM..."
8MM = 8 Major Markets

Important for Patry's PAT - SC1 to be successful. Will assist in treatment of gastric cancer - especially in China.
The good thing about biotechs are they ultimately about trying to find successful treatment regimes.